Search details
1.
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial.
Lancet Oncol
; 25(5): 614-625, 2024 May.
Article
in English
| MEDLINE | ID: mdl-38697155
2.
Metabolic adaptation towards glycolysis supports resistance to neoadjuvant chemotherapy in early triple negative breast cancers.
Breast Cancer Res
; 26(1): 29, 2024 02 19.
Article
in English
| MEDLINE | ID: mdl-38374113
3.
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial.
Lancet
; 401(10390): 1773-1785, 2023 05 27.
Article
in English
| MEDLINE | ID: mdl-37086745
4.
Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium.
Breast Cancer Res Treat
; 203(2): 351-363, 2024 Jan.
Article
in English
| MEDLINE | ID: mdl-37878152
5.
Study design for DESTINY-Breast Respond HER2-low Europe: T-DXd in patients with HER2-low advanced breast cancer.
Future Oncol
; 2024 Apr 09.
Article
in English
| MEDLINE | ID: mdl-38592002
6.
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.
N Engl J Med
; 382(7): 597-609, 2020 02 13.
Article
in English
| MEDLINE | ID: mdl-31825569
7.
ROSALINE: a phase II, neoadjuvant study targeting ROS1 in combination with endocrine therapy in invasive lobular carcinoma of the breast.
Future Oncol
; 18(22): 2383-2392, 2022 Jul.
Article
in English
| MEDLINE | ID: mdl-35695563
8.
Tumor sequencing is useful to refine the analysis of germline variants in unexplained high-risk breast cancer families.
Breast Cancer Res
; 22(1): 36, 2020 04 15.
Article
in English
| MEDLINE | ID: mdl-32295625
9.
Predictive markers for pathological complete response after neo-adjuvant chemotherapy in triple-negative breast cancer.
Ann Diagn Pathol
; 49: 151634, 2020 Dec.
Article
in English
| MEDLINE | ID: mdl-32987254
10.
Correction: Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium.
Breast Cancer Res Treat
; 2024 Apr 09.
Article
in English
| MEDLINE | ID: mdl-38592543
11.
Somatic uniparental isodisomy explains multifocality of glomuvenous malformations.
Am J Hum Genet
; 92(2): 188-96, 2013 Feb 07.
Article
in English
| MEDLINE | ID: mdl-23375657
12.
Predictive markers for pathological complete response (pCR) after neo-adjuvant chemotherapy in HER2-positive breast carcinoma.
Histol Histopathol
; 39(2): 153-164, 2024 Feb.
Article
in English
| MEDLINE | ID: mdl-37204204
13.
Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR+ Breast Cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase IIb Trial.
Clin Cancer Res
; 30(3): 532-541, 2024 02 01.
Article
in English
| MEDLINE | ID: mdl-37939105
14.
Breast Development and Cancer.
Cancers (Basel)
; 15(6)2023 Mar 13.
Article
in English
| MEDLINE | ID: mdl-36980617
15.
The Upgrade Risk of B3 Lesions to (Pre)Invasive Breast Cancer After Diagnosis on Core Needle or Vacuum Assisted Biopsy. A Belgian National Cohort Study.
Clin Breast Cancer
; 23(4): e273-e280, 2023 06.
Article
in English
| MEDLINE | ID: mdl-37085379
16.
Machine Learning Algorithm to Estimate Distant Breast Cancer Recurrence at the Population Level with Administrative Data.
Clin Epidemiol
; 15: 559-568, 2023.
Article
in English
| MEDLINE | ID: mdl-37180565
17.
Late onset toxicities associated with the use of CDK 4/6 inhibitors in hormone receptor positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) metastatic breast cancer patients: a multidisciplinary, pan-EU position paper regarding their optimal management. The GIOCONDA project.
Front Oncol
; 13: 1247270, 2023.
Article
in English
| MEDLINE | ID: mdl-37954071
18.
Real-world clinical outcomes of patients with stage I HER2-positive breast cancer treated with adjuvant paclitaxel and trastuzumab.
Crit Rev Oncol Hematol
; 190: 104089, 2023 Oct.
Article
in English
| MEDLINE | ID: mdl-37562696
19.
Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial.
Nat Commun
; 14(1): 7018, 2023 11 02.
Article
in English
| MEDLINE | ID: mdl-37919269
20.
PRDM16 (1p36) translocations define a distinct entity of myeloid malignancies with poor prognosis but may also occur in lymphoid malignancies.
Br J Haematol
; 156(1): 76-88, 2012 Jan.
Article
in English
| MEDLINE | ID: mdl-22050763